Filing Flows › bioAffinity Technologies (BIAF) › Guidance & outlook

bioAffinity Technologies (BIAF) guidance and outlook

bioAffinity Technologies' 10-Q filed Nov 6, 2026 makes 26 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 6, 2026

• We address the need for noninvasive diagnosis of lung cancer at early stage and precision diagnostics for other diseases of the lung with our proprietary platform that detects changes to the lung microenvironment using flow cytometry and automated data analysis built by machine learning, a form of AI, to preferentially target cancer cell populations and other cell populations in sputum that are indicative of a…
• Our data showed we can detect multiple targets in sputum using a combination of cellular and proteomic analysis.
• We believe that the ability to measure therapeutic targets could assist doctors in selecting among these drugs for individual patients and provide personalized medicine.
• Through our wholly owned subsidiary, OncoSelect ® Therapeutics, LLC, we continue to advance our discoveries of novel cancer therapeutic approaches that specifically and selectively target cancer cells.
• At our research laboratory, we are nurturing squamous cell skin cancer spheroids in vitro and will be treating the 3D spheroids with our self-delivering siRNAs.
• We will continue to present our findings at academic and industry conferences and expect to publish our research findings in peer-reviewed journals.
• We intend to seek strategic partners as we progress into in vivo studies to develop our therapeutics targeted at squamous and basal cell skin cancers.
• The Company intends to use the proceeds of the Offering for working capital and other general corporate purposes.
• As of November 3, 2026, we had cash and cash equivalents of $4.6 million, which we expect will support our operations through March 2027.
• We have incurred significant losses and negative cash flows from operations since inception and expect to continue to incur losses and negative cash flows for the foreseeable future.
• Based on the Company’s current expected level of operating expenditures and the cash and cash equivalents on hand at September 30, 2026, management concludes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying condensed consolidated financial statements.
• We expect to continue to incur significant operating losses for the foreseeable future as we continue the development of our diagnostic tests and advance our diagnostic tests through clinical trials.

bioAffinity Technologies' latest quarter

Questions

What does bioAffinity Technologies expect?

We address the need for noninvasive diagnosis of lung cancer at early stage and precision diagnostics for other diseases of the lung with our proprietary platform that detects changes to the lung microenvironment using flow cytometry and automated data analysis built by machine learning, a form of AI, to preferentially target cancer cell populations and other cell populations in sputum that are indicative of a… Our data showed we can detect multiple targets in sputum using a combination of cellular and proteomic analysis. We believe that the ability to measure therapeutic targets could assist

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.